Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform

Eli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.

The agreement brings together Lilly’s obesity medicines and Hims & Hers’ consumer platform. Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.